3.50Open3.50Pre Close0 Volume1 Open Interest12.50Strike Price0.00Turnover4601.20%IV10.09%PremiumJul 19, 2024Expiry Date2.49Intrinsic Value100Multiplier0DDays to Expiry1.01Extrinsic Value100Contract SizeAmericanOptions Type-0.6032Delta0.0847Gamma2.86Leverage Ratio-25.1425Theta0.0000Rho-1.73Eff Leverage0.0004Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet